Inhibitory effects of aviptadil on the SARS-CoV-2 nsp10/ nsp16 protein complex

Alnomasy, Sultan F.; Alotaibi, Bader S.; Aldosari, Ziyad M.; Mujamammi, Ahmed H.; Anand, Pragya; Akhter, Yusuf; Hasan, Mohammad R.

doi:10.21203/rs.3.rs-191980/v1

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 The SARS-CoV-2 virus enters the AT-II cell through the binding of its spike protein to the angiotensinconverting enzyme 2 surface receptors. 41 Unlike the AT-I cells, only AT-II cells express the VPAC1 receptor that VIP binds to, thus VIP and its analogues deserve special attention as a therapeutic option to combat the hypoxemic lung injury in COVID-19.…”

Section: Role Played By Aviptadil In Covid-19mentioning

confidence: 99%

Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Chakraborty

Choudhury

Lahiry³

2022

EMJ Microbiol Infect Dis

View full text Add to dashboard Cite

Despite dynamic drug and vaccine development processes to reduce the disease burden of COVID-19, the treatment options are still very limited. Vasoactive intestinal peptide (VIP) has a diversified physiological action with specific features of lung protection-related activities. VIP inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gene replication in human monocytes and the viral replication in Calu-3 cells, thus further reducing the generation of proinflammatory mediators. Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted ‘fast track’ status by the U.S. Food and Drug Administration (FDA) and to be allowed into both Phase II and III clinical trials. Initial binding of Aviptadil with non-structural protein (nsp) 10 and nsp16, which may inhibit the 2’-O-methyltransferase activity of the SARS-CoV-2 nsp10 and nsp16 complex. Aviptadil has already proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. Interim analysis results of this drug used in respiratory failure caused by SARS-CoV-2 has evolved a new hope in regard to safety and efficacy. The final results from a recently completed trial, as well as all currently ongoing trials, will clarify the class effect of this drug in the treatment of COVID-19 in future days.

show abstract

Section: Role Played By Aviptadil In Covid-19mentioning

confidence: 99%

Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Chakraborty

Choudhury

Lahiry³

2022

EMJ Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment

et al. 2022

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has swept the whole world and brought about a public health crisis of unprecedented proportions. To combat the rapid transmission and possible deaths due to the disease, researchers and companies around the world are developing all possible strategies. Due to the advantages of safety, specificity, and fewer adverse effects, polypeptide and peptidomimetic drugs are considered promising strategies. This review comprehensively summarizes and discusses the progress in development of peptide drugs for use in the treatment of COVID-19. Based on the latest results in this field, we divided them into clinically approved drugs, clinical trial drugs, and clinically ineffective drugs, and outlined the molecular targets and mechanisms of action one by one to reveal their feasibility as promising therapeutic agents for COVID-19. Notably, monoclonal antibodies have shown beneficial effects in the early stages of infection, while Paxlovid can significantly reduce hospitalization and mortality among non-vaccinated patients. Among clinical experimental drugs, both the interleukin-1 receptor antagonist anakinra and the bradykinin B2 receptor antagonist icatibant are well tolerated and effective in patients with COVID-19, but long-term trials are needed to confirm the durability of efficacy.

show abstract

Aviptadil- Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in COVID-19 Patients with Severe Respiratory Failure

Chakraborty¹,

Choudhury²,

Lahiry³

2022

Indian Journal of Respiratory Care

View full text Add to dashboard Cite

Inhibitory effects of aviptadil on the SARS-CoV-2 nsp10/ nsp16 protein complex

Cited by 3 publications

References 21 publications

Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Aviptadil: Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in Patients with COVID-19 with Severe Respiratory Failure

Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment

Aviptadil- Class Effect of a Synthetic Vasoactive Intestinal Peptide as a Treatment Option in COVID-19 Patients with Severe Respiratory Failure

Contact Info

Product

Resources

About